Home / BUSINESS / Cadila Healthcare gains on receiving EIR for Dabhasa unit

Cadila Healthcare gains on receiving EIR for Dabhasa unit

Cadila Healthcare is currently trading at Rs. 260.10, up by 2.10 points or 0.81 % from its previous closing of Rs. 258.00 on the BSE.

The scrip opened at Rs. 257.85 and has touched a high and low of Rs. 260.60 and Rs. 256.30 respectively. So far 24597 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 359.50 on 16-Jan-2019 and a 52 week low of Rs. 206.45 on 22-Aug-2019.

Last one week high and low of the scrip stood at Rs. 265.50 and Rs. 251.85 respectively. The current market cap of the company is Rs. 26381.85 crore.

The promoters holding in the company stood at 74.88 % while Institutions and Non-Institutions held 17.13 % and 8.00 % respectively.

Cadila Healthcare’s API manufacturing facility located at Dabhasa in Gujarat has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from October 7 to 11, 2019. The EIR report stated that the classification of the facility is ‘No Action Indicated (NAI)’.

Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Please share this news

Check Also

Impact of Covid-19 on E-commerce

Various restrictions were imposed to ensure social-distancing during lock down under guidelines released by Ministry …